In healthy cells, more than 90% of glutathione stays in its active, reduced form, ready to neutralize free radicals
Each 5mg vial is produced under controlled conditions using solid-phase peptide synthesis and verified through HPLC and mass spectrometry
For investigational peptides, BPC-157 has the most direct preclinical evidence specifically for bone defect healing, with the Sebecic rabbit study showing complete bony continuity in treated animals while controls remained unhealed
This occurs because oxidative stressors and toxic substances constantly affect the liver
It also acts as a localised 5-alpha reductase inhibitor, reducing DHT at the scalp level
It increases proliferation and the levels of collagen and secreted pro-matrix metalloproteinase-2 (MMP-2) in isolated human fibroblasts when used at a concentration of 1 nM